Re: Ovarian ablation or suppression in premenopausal early breast cancer: Results from the International Adjuvant Breast Cancer ovarian ablation or suppression randomized trial [3]

Journal of the National Cancer Institute

Volumn 99, Issue 17, 2007, Pages 1344-1345

  Ferretti, Gianluigi ^a   Felici, Alessandra ^a   Carlini, Paolo ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTRADIOL; ESTROGEN; FLUOROURACIL; GOSERELIN; LUTEINIZING HORMONE; METHOTREXATE; PLACEBO; PROGESTERONE; UNCLASSIFIED DRUG; ZALDEX;

AMENORRHEA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESTROGEN SYNTHESIS; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; LETTER; MENSTRUAL CYCLE; MENSTRUATION; MONOTHERAPY; OVARIECTOMY; OVARY FUNCTION; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; BREAST NEOPLASMS; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; OVARIECTOMY; PREMENOPAUSE; QUALITY OF LIFE; TAMOXIFEN;

EID: 34548563982     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm103     Document Type: Letter

References (7)

1. The Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: Results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. J Natl Cancer Inst 2007; 99:516-25.
2. Goldhirsch A, Gelber RD, Castiglione M, O'Neill A, Thurlimann B, Rudenstam CM, et al. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol 1997;8:751-6.
3. Love RR, Ba Duc N, Van Dinh N, Shen T, Havighurst TC, Allred DC, De Mets DL. Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. J Natl Cancer Inst 2002;94:662-9.
4. Hortobagyi GN. The influence of menstrual cycle phase on surgical treatment of primary breast cancer: Have we made any progress over the past 13 years? J Natl Cancer Inst 2002;94: 641-3.
5. Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998;34:632-40.
6. Baum M, Hackshaw A, Houghton J, Rutqvist Fornander T, Nordenskjold B, Nicolucci A, et al. ZIPP International Collaborators' Group. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 2006;42:895-904.
7. Castiglione-Gertsch M, ONeill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negativc breast cancer: A randomized trial. J Natl Cancer Inst 2003;95: 1833-46.